Document:

Distribution Agreement

 Exhibit 10.1 
  
 Portions of this Exhibit were omitted and filed separately with the Securities and Exchange Commission pursuant to an application for
confidential treatment. Such portions are marked by a series of asterisks. 
  
 Execution Copy 
  
 DISTRIBUTION AGREEMENT 
  
 THIS DISTRIBUTION
AGREEMENT (this “Agreement”) is made and entered into this 24th day of April 2003, by and between Medtech Holdings, Inc., a Delaware corporation with principal offices at 90 North Broadway, Irvington, New York 10533
(“Distributor”), and OraSure Technologies, Inc., a Delaware corporation with principal offices at 220 East First Street, Bethlehem, Pennsylvania 18015-1360 (“OSUR”). 
  
 BACKGROUND 
  
 OSUR has exclusive rights to develop, manufacture, market, sell and distribute the Product (as defined below) for the treatment of ordinary warts and
plantar warts by means of a refrigerant. OSUR desires to grant to Distributor the right to market, sell and distribute the Product under the Distributor Trademarks (as defined below) on an exclusive basis in certain markets within certain geographic
territories, and Distributor desires to accept such rights, all in accordance with the terms and subject to the conditions contained in this Agreement. 
  
 NOW, THEREFORE, in consideration of the foregoing, and of the mutual promises and covenants contained in this Agreement, OSUR and Distributor, intending
to be legally bound, hereby agree as follows: 
  
 1. DEFINITIONS.

  
 1.1 “Affiliate” means, when used with reference
to either Distributor or OSUR, any person or entity directly or indirectly controlling, controlled by or under common control with Distributor or OSUR, as the case may be. For purposes of this Agreement, “control” (including with
correlative meanings “controlling,” “controlled by,” or “under common control with”) means: (a) the direct or indirect ownership, in the aggregate, of at least 50% of the outstanding voting securities of an entity; (b)
the right to receive directly or indirectly, in the aggregate, at least 50% of the profits or earnings of an entity; or (c) the right or power, directly or indirectly, to direct or cause the direction of the policy decisions of an entity, whether by
ownership of voting securities, contract or otherwise. 
  
 1.2
“Assembly Contractor” means Koninklijke Utermöhlen N.V., or any successor or assignee thereof or other contractor designated by OSUR to assemble the Product purchased hereunder. 
  
 1.3 “Business Day” means any day other than a Saturday, Sunday or
day on which the Federal Reserve Bank of Philadelphia is closed. 
  
 1.4 “Contract Year” means, with respect to the first Contract Year, the period beginning on the Effective Date and ending on December 31, 2003 and, with respect to each subsequent Contract Year, the calendar year beginning on the
date immediately following the end of the preceding Contract Year. 

 1.5 “Distributor Fiscal Year” means each successive period of twelve (12) months beginning on
each April 1 during the Term (as defined in Section 11.1 hereof). 
  
 1.6 “Effective Date” means the date first written above. 
  
 1.7 “FDA” means the United States Food and Drug Administration, or any successor thereto. 
  
 1.8 “OTC Market” means the over-the-counter or consumer market within the Territory for selling Product through retail outlets in the Territory
for ultimate purchase and home use by consumers in the Territory without the assistance or intervention of, or any prescription from, a medical professional or health care practitioner. 
  
 1.9 “Product” means the patented cryosurgical removal system that (i) is developed, assembled, manufactured,
marketed and sold by OSUR or its Affiliates or designees pursuant to this Agreement, together with all modifications and improvements that may be made by OSUR to such product from time to time, for the purpose of treating ordinary warts and plantar
warts, and (ii) meets the Specifications. 
  
 1.10 “Quarterly
Period” means each successive period of three (3) months in a Contract Year with the first such three (3) month period beginning on the first day of a calendar year. 
  
 1.11 “Specifications” means the Product specifications set forth in Exhibit 1.11 to this Agreement, as such
specifications may be modified or amended pursuant to Section 8.4 of this Agreement. 
  
 1.12 “Territory” means the United States and Canada, and their respective territories and possessions. 
  
 1.13 “Unit” means a single unit of Product as described in the Specifications. 
  
 2. APPOINTMENT. 
  
 2.1 Distribution Rights. In accordance with the terms and subject to the conditions contained in this Agreement, OSUR hereby grants to Distributor,
on an exclusive basis during the Term (as defined in Section 11.1 hereof), the right to market, promote, sell and distribute the Product solely in the OTC Market in the Territory, and Distributor hereby accepts such rights. 
  
 2.2 Reservation of Rights. Distributor acknowledges and agrees that
nothing in this Agreement shall preclude OSUR from importing, marketing, manufacturing, promoting, using, selling or distributing the Products outside the Territory, or outside of the OTC Market in the Territory, either directly or indirectly
through one or more distributors, sub-distributors or agents for any purpose. 
  
 2.3 Subdistributors. In exercising its rights hereunder, Distributor may engage subdistributors or agents as provided in this Section 2.3. Distributor shall enter a written agreement with each sub-distributor
or agent, requiring the sub-distributor or agent to comply with Distributor’s obligations under this Agreement with respect to distribution of the Product in the OTC Market in the Territory. Upon request, Distributor shall provide a copy of the
sub-distributor or agent agreement to OSUR. Distributor’s use of sub-distributors or agents does not relieve Distributor of any obligations under this Agreement. 
  

 2 

 2.4 Right of First Negotiation. The parties acknowledge that there may be opportunities to
distribute the Product in the OTC Market in countries outside the Territory. If, during the Term, either party identifies such an opportunity with respect to a country outside the Territory, and OSUR elects to distribute the Product in the OTC
Market in such country, and is not precluded or limited (by contract or otherwise) in granting distribution rights to Distributor to the Product in the OTC Market in such country, OSUR will notify Distributor of its desire to distribute the Product
in the OTC Market in such country (the “Product Notice”) and may (at its option) provide Distributor a form of distribution agreement or summary of terms, which will state (among other items) the price, term, minimum purchase requirements,
and other principal terms under which OSUR is willing to grant Distributor rights to the Product in the OTC Market in such country. For a period of thirty (30) days following the date of the Product Notice, the parties shall negotiate in good faith
regarding the terms and conditions of a distribution agreement with respect thereto. If, following such 30-day period, the parties have not executed and delivered a mutually acceptable form of distribution agreement, then (i) Distributor’s
right of first negotiation with respect to all countries outside the Territory under this Section 2.4 shall terminate and (ii) OSUR shall be free to offer the right to distribute the Product in the OTC Market in any country outside the Territory.
Schedule 2.4 herein is a complete and accurate list (as of the date of this Agreement) of all countries outside the Territory where OSUR’s Histofreezer® wart removal system is sold or where agreement has been reached by OSUR with a third party to distribute such product. 
  
 2.5 Independent Contractor. Distributor is, and at all times shall be,
an independent contractor. Nothing contained in this Agreement shall be construed as constituting Distributor as an agent, partner, joint venturer or employee of OSUR, or cause OSUR to be liable for any of the debts or obligations of Distributor,
nor shall Distributor have the right or authority to act for or incur any liability or obligation of any kind, express or implied, in the name of or on behalf of OSUR or its Affiliates. 
  
 3. OBLIGATIONS. 
  
 3.1 By Distributor. 
  
 3.1.1 Level of Effort. Distributor shall use commercially reasonable efforts to market, promote, sell and distribute the Product in the OTC Market.
In connection therewith, Distributor shall maintain, at its own expense, an adequately trained staff to enable Distributor to fulfill its obligations under this Agreement. 
  
 3.1.2 Restrictions. During the Term, Distributor shall not, directly or indirectly, import, promote, market, use,
sell or otherwise distribute or provide (or arrange any promotion, marketing, use, sale, distribution or provision of) the Product (a) in any country or territory outside of the Territory (unless Distributor has acquired additional distribution
rights to such countries or territories from OSUR) or (b) in any market other than the OTC Market. Distributor shall notify OSUR of any sale or order of Product or other occurrence that violates this Section 3.1.2 promptly upon learning thereof.

  
 3.1.3 Sales Leads Outside of the Territory or OTC
Market. Distributor shall 
  

 3 

 refer to OSUR all sales leads that come to its attention with respect to the use of the Product outside of the Territory
or OTC Market and, as soon as reasonably possible, inform OSUR of the identity of such sales lead. 
  
 3.1.4 Product Labeling; Supporting Materials; Training. Distributor shall ensure that all Product purchased hereunder is distributed into the OTC
Market only with the labeling, inserts and instructions approved in writing by OSUR. Distributor shall produce and use sufficient quantities of promotional materials, including sales aids, brochures, product briefs, advertisements and similar
materials relating to the Product (including references and/descriptions on its website) for purposes of promoting, marketing, selling and distributing the Product in the OTC Market; provided that all such materials (in print, electronic or any
other type of media) shall be subject to the written approval of OSUR prior to their use (which approval shall not be unreasonably withheld or delayed). In addition, Distributor shall provide appropriate customer support to maintain and foster
customer satisfaction. 
  
 3.1.5 Compliance with Laws.
Distributor shall comply with all applicable treaties, laws, rules and regulations in connection with its promotion, marketing, use, sale or distribution of the Product in the OTC Market, its supply of the Distributor Components (as defined below)
and its performance of its obligations under this Agreement. Without limiting the generality of the foregoing, Distributor shall comply with all applicable FDA or other regulatory approvals, clearances or registrations obtained by OSUR for the sale
or distribution of the Product in the OTC Market. 
  
 3.1.6
Competition. During the Term, Distributor and its Affiliates shall not, directly or indirectly, (a) import, market, manufacture, use, promote, sell, distribute or purchase any cryosurgical wart or lesion removal product that directly competes
with the Product (a “Competing Product”) or (b) engage in, provide services for or acquire or hold an interest in any company, entity or business (as owner, stockholder, partner, co-venturer, director, officer, employee, consultant or
otherwise) that imports, manufactures, markets, promotes, sells or distributes a Competing Product. Notwithstanding the foregoing, nothing contained herein shall be deemed to prevent or preclude an entity not party to this Agreement from acquiring
an equity ownership interest in Distributor (the “Acquiring Party”) under circumstances where such Acquiring Party becomes an Affiliate of Distributor and has a business, existing prior to such acquisition, under which it imports, markets,
manufactures, uses, promotes, sells or distributes a Competing Product. In the event of such an acquisition by an Acquiring Party, OSUR shall have the right to terminate this Agreement upon not less than twelve (12) months prior written notice to
Distributor. If any provision of this Section 3.1.6 shall be held unenforceable because of scope, duration or area of its applicability, it shall be deemed modified to the extent necessary to make it enforceable, while preserving its intent.

  
 3.1.7 Marketing Plan. Distributor shall develop a
written annual plan for the marketing and sale of the Product in the OTC Market and Territory. Distributor shall deliver such plan to OSUR within thirty (30) days after the date of this Agreement. In addition, Distributor shall provide OSUR with a
written update of its marketing and sales plan at least sixty (60) days in advance of the commencement of each Distributor Fiscal Year during the Term, beginning with the Distributor Fiscal Year that begins on April 1, 2004. 
  

 4 

 3.2 By OSUR. 
  
 3.2.1 Regulatory Approvals; Compliance with Laws. The parties acknowledge that OSUR has obtained FDA clearance to
manufacture, market, sell, use and distribute the Product in the OTC Market in the United States, but has not yet sought any required regulatory approval, clearance or registration in Canada. OSUR shall have no obligation to sell or supply Product
to Distributor for sale or distribution in Canada, and Distributor shall have no right to distribute Product in Canada, until OSUR obtains any required regulatory approvals, clearances or registration for the import, distribution and sale of the
Product in the OTC Market in Canada. OSUR shall use commercially reasonable efforts to obtain such required regulatory approvals, clearances and registrations for the Product in Canada, but there is no assurance, representation or warranty that OSUR
will be successful in such efforts and its failure to obtain any such regulatory approval, clearance or registration in Canada shall not constitute a breach of this Agreement. OSUR shall use commercially reasonable efforts to maintain all approvals,
clearances or registrations of the FDA and, to the extent obtained, any regulatory authority in Canada, for the manufacturing, marketing, sale, use or distribution of the Product in the OTC Market in the Territory. All such approvals, clearances and
registrations shall be maintained in the name of OSUR. Distributor shall, at OSUR’s expense, cooperate and provide reasonable assistance and technical support in obtaining and maintaining all such approvals, clearances and registrations. OSUR
shall comply with all applicable treaties, laws, rules and regulations within the Territory, including the Quality System Regulations promulgated by the FDA, in connection with its provision of the Product to Distributor and its performance of its
obligations under this Agreement. 
  
 3.2.2 Training. OSUR
shall provide reasonable technical support and training to Distributor in the use and performance of the Product, which training shall be at times and places and for durations mutually agreed to by the parties. 
  
 3.3 Technical Support. OSUR shall provide and maintain, at its own
expense, adequate support services and a staff properly trained in all aspects of the Product to provide the Distributor with such levels of technical support throughout the Term that are commercially reasonable in light of the then current and
reasonably anticipated sales volumes of the Product in the OTC Market. 
  
 4.
SUPPLY; ORDERING AND DELIVERY. 
  
 4.1
Requirements. In accordance with the terms and subject to the conditions contained in this Agreement, OSUR shall assemble and sell to Distributor, and Distributor shall purchase from OSUR, all of Distributor’s requirements for the
Product to be marketed, sold, used or distributed in the OTC Market in the Territory. OSUR’s obligation to assemble and supply Product to Distributor shall be subject to Distributor’s compliance with its obligation to supply Distributor
Components as set forth in Section 4.2 below. 
  
 4.2 Supply of
Distributor Components. Distributor shall supply, at its sole cost, the following components and deliver such components to the Assembly Contractor, for use in packaging and assembling Products purchased hereunder (the “Distributor
Components”): 
  
 (i) Boxes for each Unit of Product with
labeling approved by OSUR; 
  

 5 

 (ii) Package inserts or instructions in form approved by OSUR; 
  
 (iii) Shipping case (standard corrugated); 
  
 (iv) Shipping case label in form approved by OSUR; 
  
 (v) Security detection devices (Checkpoint or SensorMatic); and 

 
 (vi) Transparent tamper resistant labels for box lids (if required).

  
 Distributor shall ensure that all Distributor Components are
manufactured, stored and supplied in accordance with the Specifications and all applicable treaties, laws, rules and regulations within the Territory. Distributor shall supply Distributor Components with sufficient lead-times and in sufficient
quantities as directed by OSUR to permit the packaging and assembly of Product purchased hereunder and delivery to Distributor in accordance with Distributor’s Purchase Orders (as defined in Section 4.6). 
  
 4.3 Terms and Conditions. The terms and conditions of this Agreement
shall control all sales of Product by OSUR to Distributor. No different or additional terms and conditions on any purchase order, acknowledgment or other transmittal, whether a standard business form or otherwise, utilized by Distributor or OSUR in
connection with the sale by OSUR of Product to Distributor shall be construed or deemed to be an amendment of or supplement to this Agreement or otherwise binding on either Distributor or OSUR. 
  
 4.4 Prices. 
  
 4.4.1 Product Price. 
  
 (a) Subject to Sections 4.4.2 and 4.4.5, below, Distributor shall pay OSUR
$*** for each Unit purchased hereunder (the “Price”), which Price was calculated pursuant to the following formula: 
  
 Price Calculation 
 (Per Unit) 
  
 **** 
  

 6 

 (b) The Parties acknowledge that the Total Assembly Contractor Costs for Product to be distributed in
Canada (“Canadian Product”) may be different than as set forth above because of different or additional labeling requirements in Canada. OSUR shall use commercially reasonable efforts to minimize any increase in such costs for Canadian
Product. In the event the Total Assembly Contractor Costs for Canadian Product are different than as set forth above, the Price for such Canadian Product shall be determined by incorporating such different costs in the foregoing formula and the
Price, as recalculated, shall be the Price for Canadian Product. Nothing in this Section 4.4.1(b) shall affect the Price payable for Product to be distributed in the United States. Canadian Product purchased at a different Price determined in
accordance with this Section 4.4.1(b) shall only be distributed by Distributor in Canada and all other Product purchased hereunder shall be distributed solely in the United States. 
  
 4.4.2 Price Increases. The applicable Price payable by Distributor for Product may be increased, at OSUR’s
option, at the beginning of the third Contract Year and each Contract Year thereafter during the Term, to an amount equal to the applicable Price then in effect, plus the cumulative percentage increase in the Index (as defined below) during the most
recently completed 12-month period prior to delivery of the applicable Price Increase Notice (as defined below) for which the Index data (preliminary or final) is available. By December 1 of each Contract Year, OSUR will give Distributor notice of
any increase in the Price (the “Price Increase Notice”) for Product to be purchased during the following Contract Year. For purposes of this Agreement, “Index” shall mean the Consumer Price Index of the Bureau of Labor Statistics
of the U.S. Department of Labor for Urban Wage Earners and Clerical Workers (Base Year 1982-84=100) for All Urban Areas. In the event that the compilation and/or publication of the Index shall be transferred to any other governmental department,
bureau, or agency, or shall be discontinued, then the index most nearly the same as the Index shall be used. 
  
 4.4.3 Taxes; Freight. Prices for Product are EX WORKS (Incoterms 2000) the Assembly Contractor’s facilities and are exclusive of all sales,
use, ad valorem and other similar taxes, customs, duties and other similar imports, fees and governmental charges, and freight, shipping and insurance charges. Any such charges shall be the sole responsibility of Distributor. 
  
 4.4.4 Advertising Participation. Distributor agrees to promote, market
and advertise the Product in the OTC Market in the Territory and OSUR has agreed to participate in such activities. The text of all promotional, marketing and advertising materials, programs and messages shall be subject to review and approval by
OSUR, which approval shall not be unreasonably withheld or delayed. **** 
  
 4.4.5 Price Adjustment Due to Cost Change. Immediately following the execution of this Agreement, OSUR agrees to employ commercially reasonable efforts to effect reduction in Total Assembly Contractor Costs
reflecting the additional volume associated with Distributor’s requirements hereunder. **** A Price adjustment hereunder shall take effect immediately after notice thereof is provided by OSUR to Distributor. This Section 4.4.5 shall be applied
separately to the Total Assembly Contractor Costs and related Price for Canadian Product (as defined in Section 4.4.1(b)) and the Total Assembly Contractor Costs and related Price for Product to be distributed into the United States. 
  

 7 

 4.5 Initial Stocking Order. Distributor shall place an initial stocking order for and purchase at
least 250,000 Units during the first Contract Year. Distributor shall effect such purchase through the delivery of a Purchase Order (as defined below) immediately following the execution of this Agreement. The parties shall use commercially
reasonable efforts to complete delivery of 150,000 of such Units on or prior to June 30, 2003 and shipment of the remaining 100,000 units on or prior to September 30, 2003. Distributor shall pay for such Units in accordance with Section 6.1 hereof.
Units purchased by Distributor under this Section 4.5 shall be applied towards Distributor’s minimum purchase commitment for 2003 under Section 6.2. 
  
 4.6 Purchases of Product. Distributor shall order Product by issuing binding purchase orders (each, a “Purchase Order”) to OSUR pursuant
to the terms of this Agreement. Each Purchase Order shall be subject to Section 4.3 and shall state the quantity of Product to be purchased, delivery date(s), routing instructions, destination(s) and confirmation of the applicable price hereunder.
OSUR shall indicate its acceptance or rejection of a Purchase Order within five (5) Business Days after receipt; provided that OSUR may reject a Purchase Order, in whole or in part, only if: (a) the Purchase Order fails to comply with the terms and
conditions of this Agreement; (b) the delivery date is less than one hundred twenty (120) days from the date of OSUR’s receipt of the Purchase Order (except for the initial stocking order under Section 4.5); or (c) the volume under the Purchase
Order and all other accepted Purchase Orders covering the same period exceeds the volume in Distributor’s then current forecast (delivered pursuant to Section 4.7) for such period by more than 50%. If requested by Distributor following
Distributor’s receipt of OSUR’s rejection notice under clause (c) above, OSUR will use commercially reasonable efforts to deliver the excess volume of Product specified in the rejected Purchase Order, but OSUR’s failure to so deliver
the excess volume shall not be a breach of this Agreement. OSUR’s sole obligation in filling any accepted Purchase Orders shall be to use commercially reasonable efforts to fill Distributor’s orders for Product. In no event shall OSUR be
liable to any third party for OSUR’s failure to deliver Product to Distributor by any delivery due date set forth in any Purchase Order. Each Purchase Order shall be for a minimum of 50,000 Units. 
  
 4.7 Forecasts. Within thirty (30) days after the Effective Date,
Distributor shall provide to OSUR a written forecast of Distributor’s anticipated monthly requirements for Product during the 2003 calendar year. Thereafter, no later than sixty (60) days before the beginning of each Quarterly Period during the
Term, Distributor shall provide OSUR with an additional, written forecast of Distributor’s anticipated monthly requirements for the Product during the subsequent twelve (12) month period. Each forecast required to be delivered by Distributor
under this Section 4.7 shall be nonbinding except for the first three (3) months of such forecast, which shall constitute a binding commitment to purchase by Distributor. 
  
 4.8 Shipment. OSUR shall ship Products EX WORKS (Incoterms 2000) the Assembly Contractor’s facilities. All risk
of loss, damage, spoilage, improper storage, mishandling and negligence for all Product shall pass to Distributor at the time of delivery to the shipper at the Assembly Contractor’s facilities. Distributor shall maintain insurance covering the
replacement value of such Product prior to payment of the Price therefor and shall name OSUR as an additional insured and loss payee in respect of such Product. If Distributor requests non-standard packaging, OSUR shall use reasonable efforts to
accommodate that request, provided that Distributor provides all required packaging. OSUR shall ensure that all Products are suitably packed for shipment in OSUR standard containers. OSUR shall provide to Distributor, not less than three (3)
Business Days in advance of each shipment, all necessary information relating to such shipment, including without limitation, the number of Units, cases, pallets and lot numbers. 
  

 8 

 4.9 Records. Distributor shall maintain accurate and complete records of each sale of the Product,
including without limitation, the name and address of the purchaser, the date of purchase, quantity, type and batch numbers of Product sold in each country, total volume of Product sold in the Territory, and information regarding other products that
compete with any of the Products in the Territory known to Distributor. Distributor shall maintain such records for at least three years from the date of sale, or such longer period as reasonably requested by OSUR. In addition to the foregoing,
Distributor shall comply with all record-keeping requirements imposed by the FDA or other regulatory or governmental authorities in the Territory. Upon request, Distributor shall provide OSUR with copies of any records required to be maintained
under this Section 4.9, including such records as may be necessary for OSUR to comply with all regulatory approvals related to the import, marketing, sale, use or distribution of the Products in the Territory and any other requirements of the FDA or
other regulatory authority. 
  
 5. INTELLECTUAL PROPERTY.

  
 5.1 Branding and Packaging. Product labeling,
packaging and package inserts shall be in the form approved by the FDA or other regulatory authorities in the Territory, and shall use the Compound W trademark and trade dress of Distributor (“Distributor Trademarks”), in accordance with
this Section 5.1. The parties shall cooperate in the design of the package labeling, packaging and inserts for Product, and the final Product labeling, packaging and inserts shall be subject to written approval by both parties, which shall not be
unreasonably withheld or delayed. Distributor shall be responsible for supplying adequate quantities of all packaging, labeling and package inserts in accordance with Section 4.2. Distributor hereby consents to OSUR’s use of the Distributor
Trademarks on labeling, package inserts and packaging used to assemble and ship the Product. 
  
 5.2 Promotional Materials. OSUR hereby consents to the use by Distributor of the OraSure® trademark and tradename (the “OSUR Trademark”) on promotional materials solely for the purpose of promoting, marketing and selling the Product in the OTC Market in the Territory. No
promotional materials bearing the OSUR Trademark may be used without OSUR’s prior written approval. 
  
 5.3 No Other Rights; Allocation of Goodwill. Except for the rights herein, neither party shall acquire any right, title, or interest in any
trademark, trade name, logo or trade dress, copyright, patent, or any other intellectual property rights of the other party by reason of this Agreement. Distributor acknowledges and agrees that all use of any of the OSUR Trademark and all of the
goodwill associated therewith shall inure solely to OSUR’s benefit. OSUR acknowledges and agrees that all use of any of the Distributor Trademarks and all of the goodwill associated therewith shall inure solely to Distributor’s benefit

  
 5.4 Effect of Termination. Upon termination of this
Agreement, both parties shall immediately cease all use of the other party’s trademarks, trade names, logos and trade dress, except such use as is necessary to complete the manufacturing, assembly and sale of Product under open Purchase Orders
at the time of termination, to complete the manufacturing and assembly of Product with OSUR’s remaining inventory of components therefore and to sell off such party’s Product inventory, as permitted under Section 11.3.4. 
  

 9 

 6. PAYMENT TERMS; MINIMUM PURCHASE COMMITMENTS. 
  
 6.1 Payment Terms. Distributor shall pay OSUR all amounts due under
this Agreement no later than sixty (60) days from the date of an invoice from OSUR for such amounts based on actual (not prospective) shipment. Overdue amounts shall bear interest at a rate of one percent (1%) per month or such lower rate required
by law, until paid. Distributor shall not have any right to set off or withhold any amounts due OSUR hereunder arising out of, or based upon, any counter-claim, breach of contract, tort or other action against OSUR. 
  
 6.2 Minimum Purchase Commitments. Distributor agrees to purchase at
least 250,000 Units of Product under this Agreement during each Contract Year. To the extent Distributor purchases more than 250,000 Units in any Contract Year, such excess shall not be counted towards meeting Distributor’s minimum purchase
commitment in any subsequent Contract Year. 
  
 6.3 Failure to
Meet Commitments. In the event Distributor fails to meet the applicable minimum purchase commitment set forth in Section 6.2. by the end of any Contract Year, OSUR shall have the right to convert the distribution rights granted to Distributor
hereunder to non-exclusive rights, pursuant to Section 11.2.3. If Distributor fails to purchase at least 150,000 Units of Product in any Contract Year, OSUR shall have the right to terminate this Agreement, pursuant to Section 11.2.3. 
  
 7. WARRANTIES. 
  
 Limited Product Warranties. OSUR warrants to Distributor that: (a) the Product, when shipped, will conform to the
specifications as set forth in the Specifications; (b) the Product shall be free from defects in materials and workmanship for a period equal to the stated shelf life for such Product (the “Warranty Period”); (c) the Product, when shipped,
shall not be “adulterated” or “misbranded” as those terms are defined by or pursuant to the Federal Food, Drug, and Cosmetic Act, as amended; and (d) the Product, when shipped, will have been manufactured and otherwise handled in
compliance with the Quality System Regulations then in effect, as promulgated by FDA. 
  
 7.2 OSUR DISCLAIMER. THE EXPRESS LIMITED WARRANTIES FOR THE PRODUCT SET FORTH IN SECTION 7.1. OF THIS AGREEMENT AND THE ADDITIONAL REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTION 8.1.2 OF THIS AGREEMENT ARE
IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESSED OR IMPLIED. OSUR HEREBY DISCLAIMS ANY AND ALL OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESSED OR IMPLIED, WHETHER ARISING FROM A COURSE OF DEALING OR USAGE OF TRADE,
INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. 
  

 10 

 7.3 Distributor’s Warranty Remedies. During the Warranty Period, OSUR shall replace, at
OSUR’s expense, or at Distributor’s option, refund or credit the purchase price of, any Product that does not comply with the limited warranty set forth in Section 7.1 of this Agreement. OSUR’s obligation to replace defective Products
or provide a credit or refund pursuant to this Section 7.3 shall not apply to any Products that have been subjected to misuse, mishandling, storage in a manner inconsistent with labeling, neglect, modification or unusual physical or chemical stress
after delivery to Distributor or where any defect results from the Distributor Components. This Section 7.3 states Distributor’s sole and exclusive remedy for failure of any Product to comply with the limited warranties set forth in Sections
7.1. 
  
 8. REPRESENTATIONS AND ADDITIONAL WARRANTIES; INDEMNIFICATION.

  
 8.1 Representations and Additional Warranties.

  
 8.1.1 By Distributor. Distributor represents and
warrants to OSUR as follows: (a) Distributor has full corporate power and authority to enter into and carry out its obligations under this Agreement; (b) the execution, delivery and performance of this Agreement will not conflict with, are not
inconsistent with and will not result in any breach of any terms, conditions or provisions of, or constitute (with due notice or lapse of time, or both) a default under any agreement, contract, document or instrument to which Distributor is a party
or by which it is otherwise bound; (c) this Agreement has been duly executed and delivered by Distributor and constitutes the legal, valid and binding obligation of Distributor, enforceable against Distributor in accordance with its terms; and (d)
no authorization, consent, approval or similar action of or by any third party is required for or in connection with Distributor’s authorization, execution, delivery or performance of this Agreement; and (e) the use of the Distributor
Trademarks will not constitute an infringement or dilution of a third party’s trademark rights in the Territory. 
  
 8.1.2 By OSUR. OSUR represents and warrants to Distributor as follows: (a) OSUR has full corporate power and authority to enter into and carry out
its obligations under this Agreement; (b) the execution, delivery and performance of this Agreement will not conflict with, are not inconsistent with and will not result in any breach of any terms, conditions or provisions of, or constitute (with
due notice or lapse of time, or both) a default under any agreement, contract, document or instrument to which OSUR is a party or by which it is otherwise bound; (c) this Agreement has been duly executed and delivered by OSUR and constitutes the
legal, valid and binding obligation of OSUR, enforceable against OSUR in accordance with its terms; (d) the manufacture, sale and use of the Product will not infringe upon, or constitute a misappropriation of, any third party’s intellectual
property rights; (e) no authorization, consent, approval or similar action of or by any third party is required for or in connection with OSUR’s authorization, execution, delivery or performance of this Agreement; and (f) the use of the OSUR
Trademark will not constitute an infringement or dilution of a third party’s trademark rights in the Territory. 
  
 8.2 Indemnification. 
  
 8.2.1 By Distributor. Distributor shall indemnify, defend and hold harmless OSUR, its Affiliates, and the respective directors, officers,
employees, agents and representatives of each of the foregoing, from and against any and all claims, suits and proceedings by a person or entity (other than a party to this Agreement or such party’s Affiliates) (individually and 
  

 11 

 collectively, “Claims”), and any and all losses, obligations, damages, deficiencies, costs, penalties,
liabilities, assessments, judgments, amounts paid in settlement, fines, and expenses (including court costs and reasonable fees and expenses of attorneys) in respect of any Claims (individually and collectively, “Losses”): (a) arising out
of the negligence or willful misconduct of Distributor or its Affiliates, employees, agents or any other person for whose actions Distributor is legally liable; (b) for bodily injury, personal injury, death, property damage or other injury caused by
or arising out of or in connection with the use, handling or storage of any Product by a consumer or other end-user in a manner inconsistent with the applicable package insert or labeling for such Product (including without limitation for any
indication or intended use not explicitly described or claimed in the applicable Product insert) or any misuse, mishandling or improper storage of any Product by Distributor, any subdistributor or agent of Distributor; (c) arising out of or in
connection with any promotional material, advertisement or claim made by Distributor or any subdistributor or agent of Distributor or product labeling, insert or packaging, which is not approved in writing in advance by OSUR; (d) arising out of or
in connection with a material breach by Distributor of any of its obligations under this Agreement including any representations or warranties set forth in Section 8.1.1, or the acts or omissions of any distributor, subdistributor or agent of
Distributor or any person or entity claiming to be acting pursuant to authority from Distributor; (e) the failure to manufacture or supply any Distributor Component in accordance with applicable law, the Specifications or as otherwise required under
this Agreement; or (f) arising out of any claim that any of the Distributor Trademarks constitutes an infringement or dilution of a third party’s trademark rights in the Territory; provided, however, that Distributor shall have no
liability to OSUR for any Claims or Losses to the extent that such Claims or Losses result from or arise out of: (i) the negligence or willful misconduct of OSUR or its Affiliates, employees, agents or any person for whose actions OSUR is legally
liable; (ii) a material breach by OSUR of any of its obligations under this Agreement or its representations or warranties set forth in Section 8.1.2; or (iii) any occurrence for which OSUR has liability to Distributor pursuant to Section 8.2.2.

  
 8.2.2 By OSUR. OSUR shall indemnify, defend and hold
harmless Distributor, its Affiliates, and the respective directors, officers, employees, agents and representatives of each of the foregoing, from and against any and all Claims and Losses: (a) for bodily injury, personal injury, death, property
damage or other injury caused by the defective design or manufacture of the Product (excluding the manufacture but not the design of the Distributor Components) or the inadequacy, inaccuracy and insufficiency of any product labeling approved in
writing by OSUR prior to its use, including but not limited to “CAUTION” and “WARNING” labeling; (b) arising out of the negligence or willful misconduct of OSUR or its Affiliates, employees, agents or any other person for whose
actions OSUR is legally liable; (c) arising out of or in connection with a material breach by OSUR of any of its obligations under this Agreement including any representations or warranties set forth in Section 8.1.2; (d) arising out of any claim
that the OSUR Trademark constitutes an infringement or dilution of a third party’s trademark rights in the Territory; or (e) arising out of a claim that any of the manufacture, marketing, import, sale or use of the Product infringes upon any
lawful patent rights; provided, however, that OSUR shall have no liability to Distributor for any Claims or Losses to the extent that such Claims or Losses result from or arise out of: (i) the negligence or willful misconduct of
Distributor or its Affiliates, subdistributors, employees, agents or any person for whose actions Distributor is legally liable; (ii) a material breach by Distributor of any of its obligations under this Agreement including any representations or
warranties set forth in Section 8.1.1; or (iii) any occurrence for which 
  

 12 

 Distributor has liability to OSUR pursuant to Section 8.2.1. In addition, OSUR shall have no liability to Distributor
with respect to any Claims or Losses in connection with Product labeling under clause (a), above, if such labeling is not actually distributed with the Product or Distributor fails to comply with its obligations hereunder with respect to Product
packaging, labeling, inserts, instructions and promotional materials, including Sections 3.1.4 and 4.2. 
  
 8.2.3 Indemnification Procedures. Each party shall provide prompt notice to the other of any actual or threatened Loss or Claim of which the other
becomes aware; provided, that the failure to provide prompt notice shall only be a bar to recovering Losses or Claims to the extent that a party was prejudiced by such failure. In the event of any such actual or threatened Loss or Claim, each party
shall provide the other information and assistance as the other shall reasonably request for purposes of defense, and each party shall receive from the other all necessary and reasonable cooperation in such defense including, but not limited to, the
services of employees of the other party who are familiar with the transactions or occurrences out of which any such Loss or Claim may have arisen. It shall be a condition to indemnification that the indemnifying party be allowed to control the
response to and any settlement or defense of any Claim, or the portion of any Claim, as to which indemnification is sought at the indemnifying party’s sole expense and with counsel of its own choosing. After notice from the indemnifying party
to the indemnified party of its election to assume the defense of a Claim, the indemnifying party will not be liable to the indemnified party for expenses incurred by the indemnified party in connection with such Claim under this Agreement, other
than the indemnified party’s reasonable costs of investigation or participation in such Claim, and except as provided below. The indemnified party shall have the right to employ its own counsel in any such Claim, but the fees and expenses of
such counsel incurred after notice from the indemnifying party of its assumption of the defense of such Claim shall be at the expense of the indemnified party, unless (i) the employment of counsel by the indemnified party has been authorized by the
indemnifying party, (ii) the indemnified party shall have reasonably concluded that there may be a conflict of interest between the indemnifying party and the indemnified party in the conduct of the defense of such Claim, or (iii) the indemnifying
party shall not in fact have employed counsel to assume the defense of such Claim, in each of which cases the fees and expenses of the indemnified party’s counsel shall be paid by the indemnifying party. Neither party shall have the right to
settle any Claim or agree to the entry of any judgment or other relief without the prior consent of the other party, which consent shall not be withheld unreasonably; provided that the indemnifying party may settle any Claim or agree to the entering
of any judgment or relief if such settlement, judgment or relief includes a complete release of the indemnified party from the Claims at issue. 
  
 8.3 Additional Rights for Claims of Infringement. Without limitation to any of the rights and obligations of OSUR and Distributor under Section 8.2
of this Agreement, if a third party asserts or threatens any Claim asserting: (a) that any of the manufacture, marketing, sale, use or distribution of the Product infringes upon, or constitutes a misappropriation of, such third party’s
intellectual property rights in the Territory, then OSUR may, at its option (i) procure for Distributor a license to continue selling the Product, (ii) modify such items to make them non-infringing, or (iii) if neither of the foregoing is
commercially practicable, terminate this Agreement with respect to sale of the infringing item in the jurisdiction in which infringement is asserted. 
  
 8.4 Change in Design. OSUR may, with the written consent of the Distributor (not to be unreasonably withheld), improve or modify any feature of the
Product or change in any manner the 
  

 13 

 technical specifications, features, design or performance of the Product. OSUR will use its reasonable efforts to inform
the Distributor at least sixty (60) days in advance of any such changes. OSUR will not be obliged to make any change or upgrade in any Product shipped to the Distributor prior to the official introduction of any such change or upgrade. In the event
of any change to the Product hereunder, the Specifications shall be amended to reflect such change and, as so amended, shall thereafter be deemed to be the Specifications for the Product under this Agreement. OSUR shall be responsible for obtaining
all FDA or other regulatory approvals, clearances or registrations required in the OTC Market in the Territory as a result of any change to the Product. Distributor shall have the right to submit suggested design changes and improvements to OSUR
from time to time. OSUR shall consider such improvement suggestions in good faith. 
  
 8.5 Insurance. Distributor represents, warrants, and covenants that during the Term, it shall maintain general liability insurance, including contractual liability coverage of all of Distributor’s
obligations under this Agreement, and products liability/completed operations coverage with a minimum aggregate limit of $10 million and a minimum limit per occurrence of $5 million. Such insurance shall be evidenced by one or more certificates of
insurance delivered to OSUR on an annual basis, naming OSUR as an additional insured and loss payee, and providing that OSUR shall receive at least thirty (30) days’ prior written notice of cancellation or material change of any of the policies
underlying such coverage. Any failure by Distributor to maintain the insurance coverage required by this Section 8.5 shall be a material breach of this Agreement. 
  
 9. RECALL; COMPLAINTS; REGULATORY COMPLIANCE. 
  
 9.1 Recall. Each party shall immediately notify the other in writing should it become aware of any defect or
condition that may render any Product in violation of any applicable requirement of law or regulation in the Territory or that may constitute a deviation from the warranties made by OSUR in Section 7.1. Upon the determination of OSUR to recall the
affected Product, OSUR and Distributor shall carry out any recall or replacement in full compliance with applicable laws and regulations and in the manner directed by OSUR in as expeditious a manner as possible and in such a way as to cause the
least disruption and to preserve customer goodwill and the reputation of OSUR and Distributor. OSUR shall reimburse Distributor in full for all reasonable, direct costs of the recall or replacement of a Product, but only if the recall or replacement
results from a defect in the manufacture, packaging, or labeling of the Product or from any OSUR breach of warranty, and not from any action taken or omitted by Distributor, its Affiliates or entities or persons directly controlled by Distributor or
for which it is legally responsible. The direct costs for which OSUR shall reimburse Distributor shall be limited to direct and out-of-pocket costs, such as mailing and printing costs, freight, supervised destruction and other amounts paid or
credited to third parties. OSUR shall have no liability to Distributor (or others) for indirect costs of the recall or replacement, such as lost profits, employee time, or overhead. 
  
 9.2 Consumer Communications and Complaints. 
  
 9.2.1 Communications. Distributor shall receive, collect, classify and organize routine communications from
consumers, which do not require reporting to FDA. From time to time, but not less frequently than annually or when reasonably requested by OSUR, Distributor will provide OSUR with a summary report of such communications. 
  

 14 

 9.2.2 Complaints. Distributor shall notify OSUR promptly of the receipt of any complaints
including any non-serious adverse events or reactions, improper performance or other performance related communications related to the Product and shall forward all such complaints, reports, adverse events and reactions to OSUR along with all
related information available to Distributor, as soon as practicable and in no event later than ten (10) Business Days after receipt by Distributor; provided that Distributor shall notify OSUR of any deaths or serious adverse events or reactions
within two (2) Business Days after receipt by Distributor. OSUR shall have primary responsibility for investigating and responding to all such complaints, adverse events and reactions and reporting, to the extent required, to FDA. Distributor shall
have primary responsibility for investigating and responding to consumers and the trade. Distributor and OSUR shall cooperate as necessary and useful, to investigate and respond to all complaints of any nature. OSUR shall share its investigations
and conclusions with Distributor within 10 Business Days after receipt of a potentially reportable complaint by OSUR. Information or data (if any) bearing on safety or performance of the Product in a material respect arising from sales outside the
OTC Market or Territory by OSUR or any licensee or other party authorized by OSUR shall be summarized and provided to the Distributor as reasonably required by the mutual interests of the parties, but not less frequently than annually. 

 
 9.3 Regulatory Compliance. OSUR shall assume all responsibility for
compliance with all regulatory requirements in the Territory for the handling of recalls and customer complaints, and adverse events and incidents, including, without limitation, required periodic device listing reports, the preparation of an Annual
Review of Product Quality and adverse reaction reporting, to the extent required. OSUR and Distributor agree to cooperate and coordinate the logistics of any recall or field correction with due attention to requirements of the trade, public
relations considerations and regulatory requirements. 
  
 10.
CONFIDENTIALITY AND NON-USE OF INFORMATION. 
  
 10.1
Confidential Information. 
  
 10.1.1 Definition of
“Confidential Information.” As used in this Agreement, the term “Confidential Information” shall, subject to Section 10.2 of this Agreement, mean all technical (including, without limitation, Product specifications, design,
components, compositions and formulations), financial (including, without limitation, any information obtained under Section 4.9 of this Agreement), commercial (including, without limitation, customer lists and identities) or other information of
Distributor (or any of Distributor’s Affiliates) or OSUR (or any of OSUR’s Affiliates), as applicable, irrespective of the form of communication and whether or not disclosed prior to or after the Effective Date, other than information that
was generally known or otherwise generally available to the public or the industry before disclosure to the other party, or information that becomes generally known to the public or the industry after such disclosure through no wrongful act or
omission of the receiving party. Failure to mark or otherwise identify any information as confidential or proprietary shall not adversely affect its status as “Confidential Information.” 
  
 10.1.2 Obligations of Confidentiality and Non-Use. 
  
 (a) During the Term and at all times thereafter, neither Distributor nor
OSUR shall disclose any of the other party’s Confidential Information. The foregoing shall not 
  

 15 

 prohibit disclosures: (i) made to such party’s employees, agents or advisors who have a “need to know” the
other party’s Confidential Information to the extent necessary to perform such party’s duties and obligations, or to enforce such party’s rights, under this Agreement; or (ii) compelled to be made by any requirement of law or pursuant
to any legal or investigative proceeding before any court, or governmental or regulatory authority, agency or commission so long as the party so compelled to make disclosure of Confidential Information pertaining to the other party provides prior
written notice to such other party and uses its commercially reasonable efforts to cooperate with such other party to obtain a protective order or other similar determination with respect to such Confidential Information. 
  
 (b) During the Term and at all times thereafter, Distributor and OSUR shall
not use any of the other party’s Confidential Information for its own direct or indirect benefit, or the direct or indirect benefit of any third party, except that each of Distributor and OSUR may use the other party’s Confidential
Information to the extent necessary to perform its duties and obligations, or to enforce such party’s rights, under this Agreement. 
  
 (c) Each of Distributor and OSUR shall (i) take reasonable steps, whether by instruction, agreement, or otherwise, to cause its employees, agents and
advisors who may have access to Confidential Information of the other party, to comply with its obligations under this Section 10 and (ii) shall be liable for the breach of this Section 10 by any of its employees, agents or advisors who may have
access to Confidential Information of the other party. 
  
 10.2
Exceptions. Confidential Information shall not include information that: (a) is available from governmental agencies under the United States Freedom of Information Act; (b) a party can prove on the basis of the written record, was known by
the receiving party at time of disclosure; (c) the receiving party can prove on the basis of the written record to have been independently developed for the receiving party after the time of disclosure by employees or third parties who have not had
access to corresponding Confidential Information; or (d) was received by the receiving party, without restriction, from a third party not under any obligation to the other party not to disclose it and otherwise not in violation of the other
party’s rights. 
  
 10.3 Remedies. Any breach of the
restrictions contained in this Section 10 by either Distributor or OSUR is a material breach of this Agreement, which may cause irreparable harm to the other party entitling such other party to injunctive relief in addition to all other legal
remedies. 
  
 10.4 Press Release. The parties acknowledge
that it is their intention to issue a press release concerning the execution of this Agreement. The parties shall cooperate in the preparation of such a release, which shall be subject to approval (not to be unreasonably withheld or delayed) of both
parties. 
  
 11. TERM AND TERMINATION. 
  
 11.1 Term. The term of this Agreement shall begin on the Effective
Date and end on the last day of the fifth Contract Year or on such earlier date as this Agreement may be terminated pursuant to Section 11.2 of this Agreement (the “Initial Term”). Thereafter, this Agreement shall automatically be renewed
for successive periods of one (1) year each (each, a “Renewal Term,” and together with the Initial Term, the “Term”) so long as Distributor has met its minimum purchase commitment under Section 6.2 for each Contract Year.

  

 16 

 11.2 Termination. 
  
 11.2.1 By Reason of Material Breach. This Agreement may be terminated by either Distributor or OSUR upon notice if
the other party materially breaches any term or condition of this Agreement (other than a breach covered by Section 11.2.2) and fails to remedy the breach within thirty (30) days after being given notice thereof. 
  
 11.2.2 By Reason of Failure to Pay Amounts Owing. Either OSUR or
Distributor shall have the right to terminate this Agreement if the other party shall have failed to pay timely any amounts due under this Agreement which nonpayment has not been cured within thirty (30) days of receipt of notice thereof.

  
 11.2.3 Failure to Meet Minimum Purchase Commitments. If
Distributor fails to order, accept delivery and pay for the volume of Products identified in Section 6.2 as the minimum purchase commitment for any Contract Year, then OSUR shall have the right at any time to convert Distributor’s rights
hereunder to non-exclusive rights by giving Distributor written notice of such action at least thirty (30) days prior to the effective date of such action. If Distributor fails to order, accept delivery and pay for at least 150,000 Units of the
Products in any Contract Year, then OSUR shall have the right to then terminate this Agreement by giving Distributor written notice of such action at least thirty (30) days prior to the effective date of such action. 
  
 11.2.4 By Reason of Bankruptcy or Similar Proceedings. This Agreement
may be terminated in its entirety by either party upon notice if the other party: (a) becomes the subject of any voluntary or involuntary proceeding under the U.S. Bankruptcy Code or state insolvency proceeding and such proceeding is not terminated
within sixty (60) days of its commencement; or (b) ceases to be actively engaged in business. 
  
 11.2.5 By Reason of Insurance Changes. If (i) OSUR experiences a material increase in the cost of obtaining or maintaining liability insurance coverage as a direct consequence of losses related to the sale or
distribution of Product into the OTC Market and Distributor does not agree to an increase in the Price to reimburse OSUR for such increased costs, then OSUR shall have the right to terminate this Agreement upon not less than one hundred eighty (180)
days written notice to Distributor, or (ii) OSUR is no longer able to obtain or maintain liability insurance coverage as a result of this Agreement or the sale or distribution of Product into the OTC Market, then OSUR shall have the right to
terminate this Agreement immediately upon written notice to Distributor. 
  
 11.3 Effect of Termination. 
  
 11.3.1 Subsisting Obligations. Termination or expiration of this Agreement shall not relieve the parties of any obligation arising prior to the effective date of such termination or expiration and shall not constitute a waiver of any
right of the parties under this Agreement as a result of breach or default. 
  
 11.3.2 Remedies Upon Breach. If this Agreement is validly terminated by either Distributor or OSUR pursuant to Section 11.2. of this Agreement, then subject to the limitations set forth in Sections 7.2, 7.3 and
12.5 of this Agreement, any and all rights and remedies available to the non-breaching party, whether under this Agreement, at law or in equity shall be preserved and survive the termination of this Agreement. 
  

 17 

 11.3.3 Return of Confidential Information. Upon expiration of this Agreement or its termination by
either party, each party, as the other may direct, shall destroy or return to the other promptly all tangible materials provided to it by the other that embody the other’s Confidential Information and shall erase or delete all such Confidential
Information embodied in any magnetic, optical or similar medium or stored or maintained on any information storage or retrieval device, and shall provide an officer’s certificate regarding such destruction, return, erasure or deletion.
Notwithstanding the foregoing, and subject to the provisions set forth in Section 10 of this Agreement, each party’s outside legal counsel may retain one (1) copy of such materials for archival purposes. 
  
 11.3.4 Inventory. Following expiration of this Agreement or its
termination by either party, (i) Distributor may continue selling any inventory of Product remaining in its possession for a period of six (6) months after such expiration or termination and (ii) OSUR may complete, or cause the Assembly Contractor
to complete, assembly of Product with its or the Assembly Contractor’s remaining inventory of components and Distributor shall purchase such Product and any other finished Product inventory held by OSUR or the Assembly Contractor at the Price
set forth therein and, at OSUR’s request, all remaining components not then assembled into Product remaining in OSUR’s or the Assembly Contractor’s inventory at OSUR’s cost therefor and Distributor may sell such Product and
components without limitation as to time. 
  
 11.3.5
Survival. The following Sections shall survive expiration or termination of this Agreement for any reason: Section 1, 2.3 (last sentence only), 4.3, 4.4.1, 4.4.3, 4.8, 4.9, 5.3, 5.4, 7, 8, 9, 10, 11.3, and 12. 
  
 12. GENERAL PROVISIONS. 
  
 12.1 Currency. All amounts payable under this Agreement shall be paid
in U.S. dollars, unless otherwise agreed in writing. 
  
 12.2
Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the Commonwealth of Pennsylvania, without reference to conflict of laws principles of any jurisdiction. 
  
 12.3 Force Majeure. Notwithstanding anything to the contrary set forth
herein, neither party shall be liable in damages, nor shall either party have the right to terminate this Agreement for any delay or default in performing any obligation hereunder, if such delay or default is caused by conditions beyond the control
of the relevant party, including but not limited to, acts of God, governmental restrictions or regulations, wars or insurrections, strikes, fire, floods, work-stoppages, lack of materials, and unforeseen occurrences or other occurrences beyond the
control of the affected party; provided, however, that the party so affected shall employ such reasonable actions to avoid or to remove such cause of non-performance, and shall continue performance under this Agreement with the utmost dispatch
whenever the relevant cause is abated; and further provided that if either party is unable to fulfill any relevant obligation under this Agreement due to any such cause, and this situation continues for a period of ninety (90) days, then the other
party hereto shall have the right to terminate this Agreement by written notice. 
  

 18 

 12.4 Assignment. This Agreement may not be assigned or otherwise transferred, nor may any right or
obligation under this Agreement be assigned or transferred, by either of Distributor or OSUR to a third party without the prior written consent of the other party, which consent shall not be unreasonably withheld; provided, that either of
Distributor or OSUR may transfer or assign its rights and obligations under this Agreement without consent to a successor to all or substantially all of its business or assets, whether by sale, merger, operation of law or otherwise or to the
successor by purchase or otherwise of such party’s line of business to which this Agreement relates. 
  
 12.5 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES ARISING IN ANY WAY OUT
OF THIS AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, INCLUDING, WITHOUT LIMITATION, PUNITIVE DAMAGES, LOST PROFITS AND THE COST OF REPLACEMENT PRODUCT OR GOODS. THIS LIMITATION WILL APPLY EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGE. NOTHING IN THIS SECTION 12.5 SHALL PRECLUDE THE INCLUSION OF SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES INCURRED BY ANY PARTY ENTITLED TO INDEMNIFICATION UNDER SECTION 8.2 OF THIS AGREEMENT IN CONNECTION WITH
ANY THIRD PARTY CLAIM, SUIT OR ACTION AGAINST SUCH PARTY WITHIN THE AMOUNT OF LOSSES INCURRED AS A RESULT OF SUCH THIRD PARTY CLAIM OR ACTION. 
  
 12.6 No Third Party Beneficiaries. Distributor and OSUR intend that only Distributor and OSUR will benefit from, and are entitled to enforce the
provisions of, this Agreement. No third party beneficiary is intended under this Agreement. 
  
 12.7 Modifications; Waiver. No modification to this Agreement shall be effective unless such modification is in a writing, which is signed by a duly authorized representative of each of Distributor and OSUR. No
waiver of any rights or breach or default under this Agreement shall be effective unless assented to in writing by the party to be charged with such waiver. The waiver of any breach or default shall not constitute a waiver of any other right
hereunder or any subsequent breach or default. 
  
 12.8
Notices. Any required notices under this Agreement shall be given in writing at the address of each party set forth above, or to such other address as either party may substitute by written notice to the other in the manner contemplated in
this Section 12.8, and shall be deemed given (a) when personally delivered; (b) if sent by recognized overnight courier service, on the next business day after deposit with such courier, properly addressed and fee prepaid; (c) if sent by U.S.
certified mail, return receipt requested, on the fourth (4th) Business Day after deposit in the U.S. mail, properly addressed and postage prepaid; or (d) if sent by facsimile, upon and after the receipt of a machine-generated written confirmation
report corresponding to the notice given evidencing the proper facsimile number of the receiving party, provided a copy of such notice is also sent by regular first-class U.S. mail. All notices shall be sent to the attention of the recipient’s
president. 
  
 12.9 Descriptive Headings. The headings of
the several sections of this Agreement are intended for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 
  

 19 

 12.10 Severability. In the event that any provision of this Agreement becomes or is declared by a
court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without such provision; provided that this severability provision shall not be effective if it materially changes the
economic benefit of this Agreement to either Distributor or OSUR. 
  
 12.11 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument. A facsimile transmission of a signed original
shall have the same effect as delivery of the signed original. 
  
 12.12 Expenses. Except as otherwise expressly set forth in this Agreement, Distributor and OSUR shall bear their own respective expenses incident to the preparation, negotiation, execution and delivery of this Agreement and to the
performance of their respective obligations under this Agreement. 
  
 12.13 Alternate Dispute Resolution. 
  
 12.13.1
Agreement to utilize Alternate Dispute Resolution . Except for matters which relate to the enforcement of Section 10 of this Agreement, which matters shall not be required to be submitted to mediation or arbitration, any controversy or claim
between Distributor and OSUR arising out of or relating to this Agreement, or any breach of this Agreement, including without limitation, any claim that this Agreement, or any part thereof, is invalid, illegal or otherwise voidable or void, shall be
submitted to neutral third party dispute resolution in the form of mediation before a mutually selected and agreed upon mediator who shall be neutral and experienced in the type of business contemplated herein. Should the parties be unable to agree
on a mediator or should mediation fail, the parties shall then submit the dispute to arbitration before and in accordance with the then current commercial arbitration rules of the American Arbitration Association. Judgment upon an arbitration award
may be entered in any court having competent jurisdiction and shall be binding, final and non-appealable. No punitive or exemplary damages shall be awarded against either Distributor or OSUR. This Section 12.13.1 shall be deemed to be
self-executing, and in the event either party fails to appear at any properly noticed arbitration proceeding, an award may be entered against such party notwithstanding said failure to appear. Such arbitration shall take place in a neutral location
as the parties may mutually agree. Each party shall bear its own costs incurred in connection with the mediation or arbitration proceeding. 
  
 12.13.2 Right to Seek Injunctive Relief Preserved. Nothing in the Agreement shall be construed as limiting or precluding either party from bringing
any action in any court of competent jurisdiction for injunctive or other extraordinary relief as such party deems necessary or appropriate to compel the other party to comply with its obligations under Section 10 of this Agreement. 
  
 12.14 Entire Agreement. This Agreement constitutes the entire and
exclusive agreement and understanding between Distributor and OSUR with respect to the subject matter of this Agreement, and supersedes and cancels all previous negotiations, agreements, and commitments, whether oral or in writing, in respect to the
subject matter of this Agreement. 
  
 [The remainder of this page
left blank] 
  

 20 

 IN WITNESS WHEREOF, the undersigned duly authorized officers of OSUR and Distributor, respectively,
hereby execute this Agreement on the date first above written on behalf of OSUR and Distributor, respectively. 
  

			
	 ORASURE TECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Mike Gausling

	 Print Name:
	 	 Mike Gausling

	 Title:
	 	 President and CEO

	
	 MEDTECH HOLDINGS, INC.

		
	 By:
	 	 /s/ Peter J. Anderson

	 Print Name:
	 	 Peter J. Anderson

	 Title:
	 	 CFO

  

 21 

 Exhibit 1.11 
  
 Product Specifications 
  

Document Attached 
  

 22 

 Product Specifications 
  
 1 “Unit” of Product shall consist of: 
  
 Supplied by OSUR: 
  

	 	•	1 110ml aluminum canister filled with 80 ml of Cryogenic gas mixture, printed in 4 colors (drawing enclosed). 

  

	 	•	12 5-mm foam applicators packaged in a transparent zip lock bag (drawing enclosed) 

  
 Supplied by Distributor: 
  

	 	•	1 white virgin sulphate cardboard box (18 points) printed in 4 colors 

 Artwork and labeling to be approved by OSUR 
  

	 	•	1 instructions for use leaflet printed in 4 colors 

 Content to be approved by OSUR 
  

	 	•	1 shipping case (corrugated carton) 

  

	 	•	1 shipping case label Artwork and content to be approved by OSUR 

  

	 	•	2 transparent tamper evidence labels for the lids of the box (if required) 

  

	 	•	1 anti theft detector 

  
 (Drawings Omitted) 
  

 23 

 Exhibit 2.4 
  
 Countries outside the United States where the Histofreezer® wart removal system is sold: 
  

Belgium 
 The Netherlands 
 Finland 
 Sweden 
 Norway 
 Denmark 
 Iceland

 Germany 
 Austria 
 Switzerland 
 France 
 Spain 
 Portugal 
 Italy 
 Turkey 
 UK 

Ireland 
 Greece 
 Romania 
 Slovenia 
 Cyprus 
 South Africa 
 Australia 
 Hong Kong 
 Singapore 
 South Korea 
 China 
 Israel 
 Mexico 
 Brazil 
  

 242000 Stock Award Plan

 Exhibit 10.2 
  
 ORASURE TECHNOLOGIES, INC. 
  
 2000 STOCK AWARD PLAN 
  
 ARTICLE 1 
 ESTABLISHMENT AND PURPOSE

 (Amended Effective as of May 18, 2004) 
  
 Establishment. Epitope, Inc. established this Plan as the Epitope, Inc. 2000 Stock Award Plan, effective as of February 15, 2000, subject to
shareholder approval as provided in Article 17. Effective September 29, 2000, in connection with the merger of Epitope, Inc. with and into OraSure Technologies, Inc., the name of the Plan was changed to the OraSure Technologies, Inc. 2000 Stock
Award Plan and the Plan was adopted as a stock option plan of OraSure Technologies, Inc. 
  
 1.1 Purpose. The purpose of the Plan is to promote and advance the interests of Corporation and its shareholders by enabling Corporation to attract, retain, and reward employees, outside advisors, and directors
of Corporation and its subsidiaries. It is also intended to strengthen the mutuality of interests between such employees, advisors, and directors and Corporation’s shareholders. The Plan is designed to meet this intent by offering stock options
and other equity-based incentive awards, thereby providing a proprietary interest in pursuing the long-term growth, profitability, and financial success of Corporation. 
  
 ARTICLE 2 
 DEFINITIONS 
  
 2.1 Defined Terms. For
purposes of the Plan, the following terms have the meanings set forth below: 
  
 “Advisor” means a natural person who is a consultant to or member of an Advisory Committee of Corporation or a Subsidiary, who provides bona fide services to Corporation and who is neither an
employee of Corporation or a Subsidiary nor a Non-Employee Director. “Advisor” excludes any person who provides services to Corporation in connection with the offer or sale of securities in a capital raising transaction or to promote or
maintain a market for Corporation’s securities, and any other person excluded from the class of persons to whom securities may be offered pursuant to a registration statement on Form S-8 or any successor form of registration statement.

  
 “Advisory Committee” means a
scientific advisory committee to Corporation or a Subsidiary. 
  
 “Award” means an award or grant made to a Participant of Options, Stock Appreciation Rights, Restricted Awards, Performance Awards, or Other Stock-Based Awards pursuant to the Plan. 

 “Award Agreement” means an agreement as described in Section 6.4. 
  
 “Board” means the Board of Directors of Corporation.

  
 “Code” means the Internal Revenue Code
of 1986, as amended and in effect from time to time, or any successor thereto, together with rules, regulations, and interpretations promulgated thereunder. Where the context so requires, any reference to a particular Code section will be construed
to refer to the successor provision to such Code section. 
  
 “Committee” means the committee appointed by the Board to administer the Plan as provided in Article 3 of the Plan. 
  
 “Common Stock” means the Common Stock, no par value, of Corporation or any security of Corporation issued in substitution, in
exchange, or in lieu of such stock. 
  
 “Continuing
Restriction” means a Restriction contained in Sections 6.7, 6.8, and 16.4 of the Plan and any other Restrictions expressly designated by the Committee in an Award Agreement as a Continuing Restriction. 
  
 “Corporation” means OraSure Technologies, Inc., a
Delaware corporation, or any successor corporation. As to awards granted or other action taken prior to September 29, 2000, “Corporation” includes Epitope, Inc., as predecessor to OraSure Technologies, Inc. 
  
 “Deferred Compensation Option” means a Nonqualified
Option granted with an option price less than Fair Market Value on the date of grant pursuant to Section 7.9 of the Plan. 
  
 “Disability” means the condition of being “disabled” within the meaning of Section 422(c)(6) of the Code. However, the
Committee may change the foregoing definition of “Disability” or may adopt a different definition for purposes of specific Awards. 
  
 “Exchange Act” means the Securities Exchange Act of 1934, as amended and in effect from time to time, or any successor statute.
Where the context so requires, any reference to a particular section of the Exchange Act, or to any rule promulgated under the Exchange Act, shall be construed to refer to successor provisions to such section or rule. 
  
 “Fair Market Value” means with respect to Common
Stock, on a particular day, without regard to any restrictions (other than a restriction which, by its terms, will never lapse), the mean between the reported high and low sale prices, or, if there is no sale on such day, the mean between the
reported bid and asked prices, of Shares of the Common Stock on that day or, if that day is not a trading day, the last prior trading day, on the securities exchange or automated securities interdealer quotation system on which such Shares have been
traded. 
  
 “Incentive Stock Option” or
“ISO” means any Option granted pursuant to the Plan that is intended to be and is specifically designated in its Award Agreement as an “incentive stock option” within the meaning of Section 422 of the Code.

  
 “Non-Employee Director” means a member
of the Board who is not an employee of Corporation or any Subsidiary. 
  

 2 

 “Nonqualified Option” or “NQO” means any Option,
including a Deferred Compensation Option, granted pursuant to the Plan that is not an Incentive Stock Option. 
  
 “Option” means an ISO, an NQO, or a Deferred Compensation Option. 
  
 “Other Stock-Based Award” means an Award as defined in Section 11.1. 
  
 “Participant” means an employee of Corporation or a
Subsidiary, an Advisor, or a Non-Employee Director who is granted an Award under the Plan. 
  
 “Performance Award” means an Award granted pursuant to the provisions of Article 10 of the Plan, the Vesting of which is contingent on performance attainment. 
  
 “Performance Cycle” means a designated performance
period pursuant to the provisions of Section 10.3 of the Plan. 
  
 “Performance Goal” means a designated performance objective pursuant to the provisions of Section 10.4 of the Plan. 
  
 “Plan” means this OraSure Technologies, Inc. 2000 Stock Award Plan, as set forth herein and as it may be amended from time to
time. 
  
 “Reporting Person” means a
Participant who is subject to the reporting requirements of Section 16(a) of the Exchange Act. 
  
 “Restricted Award” means a Restricted Share or a Restricted Unit granted pursuant to Article 9 of the Plan. 
  
 “Restricted Share” means an Award described in Section 9.1(a) of the Plan. 
  
 “Restricted Unit” means an Award of units
representing Shares described in Section 9.1(b) of the Plan. 
  
 “Restriction” means a provision in the Plan or in an Award Agreement which limits the exercisability or transferability, or which governs the forfeiture, of an Award or the Shares, cash, or other property payable
pursuant to an Award. 
  
 “Retirement”
means: 
  
 (a) For Participants who are
employees, retirement from active employment with Corporation and its Subsidiaries at or after age 50, or such earlier retirement date as approved by the Committee for purposes of the Plan; 
  
 (b) For Participants who are Non-Employee Directors,
termination of membership on the Board after attaining age 50, or such earlier retirement date as approved by the Committee for purposes of the Plan; and 
  

 3 

 (c) For Participants who are Advisors, termination of service as an Advisor after
attaining age 50, or such earlier retirement date as approved by the Committee for purposes of the Plan. 
  
 However, the Committee may change the foregoing definition of “Retirement” or may adopt a different definition for purposes of specific Awards. 
  
 “Share” means a share of Common Stock. 
  
 “Stock Appreciation Right” or “SAR” means an Award to benefit from the
appreciation of Common Stock granted pursuant to the provisions of Article 8 of the Plan. 
  
 “Subsidiary” means any “subsidiary corporation” of Corporation within the meaning of Section 424 of the Code, namely any corporation in which Corporation directly or indirectly
controls 50 percent or more of the total combined voting power of all classes of stock having voting power. 
  
 “Vest” or “Vested” means: 
  
 (a) In the case of an Award that requires exercise, to be or to become immediately and fully exercisable and
free of all Restrictions (other than Continuing Restrictions); 
  
 (b) In the case of an Award that is subject to forfeiture, to be or to become nonforfeitable, freely transferable, and free of all Restrictions (other than Continuing Restrictions); 
  
 (c) In the case of an Award that is required to be earned by
attaining specified Performance Goals, to be or to become earned and nonforfeitable, freely transferable, and free of all Restrictions (other than Continuing Restrictions); or 
  
 (d) In the case of any other Award as to which payment is not dependent solely upon the exercise of a right,
election, exercise, or option, to be or to become immediately payable and free of all Restrictions (except Continuing Restrictions). 
  
 2.2 Gender and Number. Except where otherwise indicated by the context, any masculine or feminine terminology used in the Plan shall also include
the opposite gender; and the definition of any term in Section 2.1 in the singular shall also include the plural, and vice versa. 
  
 ARTICLE 3 
 ADMINISTRATION

  
 3.1 General. Except as provided in Section 3.7, the
Plan will be administered by a Committee composed as described in Section 3.2. 
  

 4 

 3.2 Composition of the Committee. The Committee will be appointed by the Board from among its
members in a number and with such qualifications as will meet the requirements for approval by a committee pursuant to both Rule 16b-3 under the Exchange Act and Section 162m of the Code. The Board may from time to time remove members from, or add
members to, the Committee. Vacancies on the Committee, however caused, will be filled by the Board. The initial members of the Committee will be the members of Corporation’s existing Executive Compensation Committee. The Board may at any time
replace the Executive Compensation Committee with another Committee. In the event that the Executive Compensation Committee ceases to satisfy the requirements of Rule 16b-3 or Section 162m of the Code, the Board will appoint another Committee
satisfying such requirements. 
  
 3.3 Authority of the
Committee. The Committee will have full power and authority (subject to such orders or resolutions as may be issued or adopted from time to time by the Board) to administer the Plan in its sole discretion, including the authority to: 

 
 (a) Construe and interpret the Plan and any Award
Agreement; 
  
 (b) Promulgate, amend, and rescind
rules and procedures relating to the implementation of the Plan; 
  
 (c) With respect to employees and Advisors: 
  
 (i) Select the employees and Advisors who shall be granted Awards; 
  
 (ii) Determine the number and types of Awards to be granted to each such Participant; 
  
 (iii) Determine the number of Shares, or Share equivalents,
to be subject to each Award; 
  
 (iv) Determine
the option price, purchase price, base price, or similar feature for any Award; and 
  
 (v) Determine all the terms and conditions of all Award Agreements, consistent with the requirements of the Plan. 
  
 Decisions of the Committee, or any delegate as permitted by the Plan, shall be final,
conclusive, and binding on all Participants. 
  
 3.4 Action by
the Committee. A majority of the members of the Committee will constitute a quorum for the transaction of business. Action approved by a majority of the members present at any meeting at which a quorum is present, or action in writing by all the
members of the Committee, will be the valid acts of the Committee. 
  
 3.5 Delegation. Notwithstanding the foregoing, the Committee may delegate to one or more officers of Corporation the authority to determine the recipients, types, amounts, and terms of Awards granted to Participants who are not
Reporting Persons. 
  

 5 

 3.6 Liability of Committee Members. No member of the Committee will be liable for any action or
determination made in good faith with respect to the Plan, any Award, or any Participant. 
  
 3.7 Awards to Non-Employee Directors. The Board or Committee may grant Awards from time to time to Non-Employee Directors. 
  
 3.8 Costs of Plan. The costs and expenses of administering the Plan will be borne by Corporation. 
  
 ARTICLE 4 
 DURATION OF THE PLAN AND SHARES SUBJECT TO THE PLAN 
  
 4.1 Duration of the Plan. The Plan is effective February 15, 2000, subject to approval by Epitope, Inc.’s shareholders as provided in Article
17. The Plan will remain in effect until Awards have been granted covering all the available Shares or the Plan is otherwise terminated by the Board. Termination of the Plan will not affect outstanding Awards. 
  
 4.2 Shares Subject to the Plan. 
  
 4.2.1 General. The shares which may be made subject to Awards under
the Plan are Shares of Common Stock, which may be either authorized and unissued Shares or reacquired Shares. No fractional Shares may be issued under the Plan. 
  

4.2.2 Number of Shares. The maximum number of Shares for which Awards may be granted under the Plan is 7,300,000 Shares, plus the number of
Shares that are available for grant under the Epitope, Inc., 1991 Stock Award Plan (the “1991 Plan”), on February 15, 2000, subject to adjustment pursuant to Article 14 of the Plan. 
  
 4.2.3 Availability of Shares for Future Awards. If an Award under the
Plan, the 1991 Plan, or the Incentive Stock Option Plan for Key Employees of Epitope, Inc. (the “ISOP”), is canceled or expires for any reason prior to having been fully Vested or exercised by a Participant or is settled in cash in lieu of
Shares or is exchanged for other Awards, all Shares covered by such Awards will be made available for future Awards under the Plan. Furthermore, any Shares used as full or partial payment to Corporation by a Participant of the option, purchase, or
other exercise price of an Award and any Shares covered by a Stock Appreciation Right which are not issued upon exercise will become available for future Awards. 
  
 ARTICLE 5 
 ELIGIBILITY 
  
 5.1 Employees and Advisors.
Officers and other employees of Corporation and any Subsidiaries (who may also be directors of Corporation or a Subsidiary) and Advisors who, in the Committee’s judgment, are or will be contributors to the long-term success of Corporation will
be eligible to receive Awards under the Plan. 
  

 6 

 5.2 Non-Employee Directors. All Non-Employee Directors will be eligible to receive Awards as
provided in Section 3.7 of the Plan. 
  
 ARTICLE 6

 AWARDS 
  
 6.1 Types of Awards. The types of Awards that may be granted under the Plan are: 
  
 (a) Options governed by Article 7 of the Plan; 
  
 (b) Stock Appreciation Rights governed by Article 8 of the
Plan; 
  
 (c) Restricted Awards governed by
Article 9 of the Plan; 
  
 (d) Performance Awards
governed by Article 10 of the Plan; and 
  
 (e)
Other Stock-Based Awards or combination awards governed by Article 11 of the Plan. 
  
 In the discretion of the Committee, any Award may be granted alone, in addition to, or in tandem with other Awards under the Plan. 
  
 6.2 General. Subject to the limitations of the Plan, the Committee may cause Corporation to grant Awards to such Participants, at such times, of
such types, in such amounts, for such periods, with such option prices, purchase prices, or base prices, and subject to such terms, conditions, limitations, and restrictions as the Committee, in its discretion, deems appropriate. Awards may be
granted as additional compensation to a Participant or in lieu of other compensation to such Participant. A Participant may receive more than one Award and more than one type of Award under the Plan. 
  
 6.3 Nonuniform Determinations. The Committee’s determinations
under the Plan or under one or more Award Agreements, including without limitation, (a) the selection of Participants to receive Awards, (b) the type, form, amount, and timing of Awards, (c) the terms of specific Award Agreements, and (d) elections
and determinations made by the Committee with respect to exercise or payments of Awards, need not be uniform and may be made by the Committee selectively among Participants and Awards, whether or not Participants are similarly situated. 

 
 6.4 Award Agreements. Each Award will be evidenced by a written
Award Agreement between Corporation and the Participant. Award Agreements may, subject to the provisions of the Plan, contain any provision approved by the Committee. 
  

 7 

 6.5 Provisions Governing All Awards. All Awards will be subject to the following provisions:

  
 (a) Alternative Awards. If any Awards
are designated in their Award Agreements as alternative to each other, the exercise of all or part of one Award automatically will cause an immediate equal (or pro rata) corresponding termination of the other alternative Award or Awards. 

 
 (b) Rights as Shareholders. No Participant will
have any rights of a shareholder with respect to Shares subject to an Award until such Shares are issued in the name of the Participant. 
  
 (c) Employment Rights. Neither the adoption of the Plan nor the granting of any Award will confer on any person the right to
continued employment with Corporation or any Subsidiary or the right to remain as a director of Corporation or a member of any Advisory Committee, as the case may be, nor will it interfere in any way with the right of Corporation or a Subsidiary to
terminate such person’s employment or to remove such person as an Advisor or as a director at any time for any reason or for no reason, with or without cause. 
  
 (d) Termination Of Employment. The terms and conditions under which an Award may be exercised or will
continue to Vest, if at all, after a Participant’s termination of employment or service as an Advisor or as a Non-Employee Director will be determined by the Committee and specified in the applicable Award Agreement. 
  
 (e) Change in Control. The Committee, in its
discretion, may provide in any Award Agreement that in the event of a change in control of Corporation (as the Committee may define such term in the Award Agreement), as of the date of such change in control: 
  
 (i) All, or a specified portion of, Awards requiring
exercise will become fully and immediately exercisable, notwithstanding any other limitations on exercise; 
  
 (ii) All, or a specified portion of, Awards subject to Restrictions will become fully Vested; and 
  
 (iii) All, or a specified portion of, Awards subject to
Performance Goals will be deemed to have been fully earned. 
  
 The Committee, in its discretion, may include change in control provisions in some Award Agreements and not in others, may include different change in control provisions in different Award Agreements, and may include change in control
provisions for some Awards or some Participants and not for others. 
  
 (f) Service Periods. At the time of granting Awards, the Committee may specify, by resolution or in the Award Agreement, the period or periods of service performed or to be performed by the Participant in
connection with the grant of the Award. 
  

 8 

 6.6 Tax Withholding. 
  
 (a) General. Corporation will have the right to deduct from any settlement, including the delivery or
Vesting of Shares, made under the Plan any federal, state, or local taxes of any kind required by law to be withheld with respect to such payments or to take such other action as may be necessary in the opinion of Corporation to satisfy all
obligations for the payment of such taxes. The recipient of any payment or distribution under the Plan will make arrangements satisfactory to Corporation for the satisfaction of any such withholding tax obligations. Corporation will not be required
to make any such payment or distribution under the Plan until such obligations are satisfied. 
  
 (b) Stock Withholding. The Committee, in its sole discretion, may permit a Participant to satisfy all or a part of the withholding
tax obligations incident to the settlement of an Award involving payment or delivery of Shares to the Participant by having Corporation withhold a portion of the Shares that would otherwise be issuable to the Participant. Such Shares will be valued
based on their Fair Market Value on the date the tax withholding is required to be made. Any stock withholding with respect to a Reporting Person will be subject to such limitations as the Committee may impose to comply with the requirements of the
Exchange Act. 
  
 6.7 Annulment of Awards. Any Award
Agreement may provide that the grant of an Award payable in cash is provisional until cash is paid in settlement thereof or that grant of an Award payable in Shares is provisional until the Participant becomes entitled to the certificate in
settlement thereof. In the event the employment (or service as an Advisor or membership on the Board) of a Participant is terminated for cause (as defined below), any Award that is provisional will be annulled as of the date of such termination for
cause. For the purpose of this Section 6.7, the term “for cause” has the meaning set forth in the Participant’s employment agreement, if any, or otherwise means any discharge (or removal) for material or flagrant violation of the
policies and procedures of Corporation or for other job performance or conduct which is materially detrimental to the best interests of Corporation, as determined by the Committee. 
  
 6.8 Engaging in Competition With Corporation. Any Award Agreement may provide that, if a Participant terminates
employment with Corporation or a Subsidiary for any reason whatsoever, and within 18 months after the date thereof accepts employment with any competitor of (or otherwise engages in competition with) Corporation, the Committee, in its sole
discretion, may require such Participant to return to Corporation the economic value of any Award that is realized or obtained (measured at the date of exercise, Vesting, or payment) by such Participant at any time during the period beginning on the
date that is six months prior to the date of such Participant’s termination of employment with Corporation. 
  

 9 

 ARTICLE 7 
 OPTIONS 
  
 7.1 Types of
Options. Options granted under the Plan may be in the form of Incentive Stock Options or Nonqualified Options (including Deferred Compensation Options). The grant of each Option and the Award Agreement governing each Option will identify the
Option as an ISO or an NQO. In the event the Code is amended to provide for tax-favored forms of stock options other than or in addition to Incentive Stock Options, the Committee may grant Options under the Plan meeting the requirements of such
forms of options. 
  
 7.2 General. Options will be subject
to the terms and conditions set forth in Article 6 and this Article 7 and may contain such additional terms and conditions, not inconsistent with the express provisions of the Plan, as the Committee (or the Board with respect to Awards to
Non-Employee Directors) deems desirable. 
  
 7.3 Option
Price. Each Award Agreement for Options will state the option exercise price per Share of Common Stock purchasable under the Option, which will not be less than: 
  
 (a) $1 per share in the case of a Deferred Compensation Option; 
  
 (b) 75 percent of the Fair Market Value of a Share on the
date of grant for all other Nonqualified Options; or 
  
 (c) 100 percent of the Fair Market Value of a Share on the date of grant for all Incentive Stock Options. 
  
 7.4 Option Term. The Award Agreement for each Option will specify the term of each Option, which may be unlimited or may have a specified period
during which the Option may be exercised, as determined by the Committee. 
  
 7.5 Time of Exercise. The Award Agreement for each Option will specify, as determined by the Committee: 
  
 (a) The time or times when the Option will become exercisable and whether the Option will become exercisable in full or in graduated
amounts over a period specified in the Award Agreement; 
  
 (b) Such other terms, conditions, and restrictions as to when the Option may be exercised as determined by the Committee; and 
  

(c) The extent, if any, to which the Option will remain exercisable after the Participant ceases to be an employee, Advisor, or
director of Corporation or a Subsidiary. 
  
 An Award Agreement for an Option may,
in the discretion of the Committee, provide whether, and to what extent, the Option will become immediately and fully exercisable (i) in the event of the death, Disability, or Retirement of the Participant, or (ii) upon the occurrence of a change in
control of Corporation. 
  

 10 

 7.6 Method of Exercise. The Award Agreement for each Option will specify the method or methods of
payment acceptable upon exercise of an Option. An Award Agreement may provide that the option price is payable in full in cash or, at the discretion of the Committee: 
  
 (a) In installments on such terms and over such period as the Committee determines; 
  
 (b) In previously acquired Shares (including Restricted
Shares); 
  
 (c) By surrendering outstanding
Awards under the Plan denominated in Shares or in Share-equivalent units; 
  
 (d) By delivery (in a form approved by the Committee) of an irrevocable direction to a securities broker acceptable to the Committee: 
  
 (i) To sell Shares subject to the Option and to deliver all or a part of the sales proceeds to Corporation
in payment of all or a part of the option price and withholding taxes due; or 
  
 (ii) To pledge Shares subject to the Option to the broker as security for a loan and to deliver all or a part of the loan proceeds to
Corporation in payment of all or a part of the option price and withholding taxes due; or 
  
 (e) In any combination of the foregoing or in any other form approved by the Committee. 
  
 If Restricted Shares are surrendered in full or partial payment of an Option price, a
corresponding number of the Shares issued upon exercise of the Option will be Restricted Shares subject to the same Restrictions as the surrendered Restricted Shares. 
  
 7.7 Special Rules for Incentive Stock Options. In the case of an Option designated as an Incentive Stock Option, the
terms of the Option and the Award Agreement must be in conformance with the statutory and regulatory requirements specified in Section 422 of the Code, as in effect on the date such ISO is granted. ISOs may be granted only to employees of
Corporation or a Subsidiary. ISOs may not be granted under the Plan after February 15, 2010, unless the ten-year limitation of Section 422(b)(2) of the Code is removed or extended. 
  
 7.8 Restricted Shares. In the discretion of the Committee, the Shares issuable upon exercise of an Option may be
Restricted Shares if so provided in the Award Agreement. 
  
 7.9
Deferred Compensation Options. The Committee may, in its discretion, grant Deferred Compensation Options with an option price less than Fair Market Value to provide a means for deferral of compensation to future dates. The option price will
be determined by the Committee subject to Section 7.3(a) of the Plan. The number of Shares subject to a Deferred 
  

 11 

 Compensation Option will be determined by the Committee, in its discretion, by dividing the amount of compensation to be
deferred by the difference between the Fair Market Value of a Share on the date of grant and the option price of the Deferred Compensation Option. Amounts of compensation deferred with Deferred Compensation Options may include amounts earned under
Awards granted under the Plan or under any other compensation program or arrangement of Corporation as permitted by the Committee. The Committee may grant Deferred Compensation Options only if it reasonably determines that the recipient of such an
Option is not likely to be deemed to be in constructive receipt for income tax purposes of the income being deferred. 
  
 7.10 Reload Options. The Committee, in its discretion, may provide in an Award Agreement for an Option that in the event all or a portion of the
Option is exercised by the Participant using previously acquired Shares, the Participant will automatically be granted a replacement Option (with an option price equal to the Fair Market Value of a Share on the date of such exercise) for a number of
Shares equal to (or equal to a portion of) the number of shares surrendered upon exercise of the Option. Such reload Option features may be subject to such terms and conditions as the Committee shall determine, including without limitation, a
condition that the Participant retain the Shares issued upon exercise of the Option for a specified period of time. 
  
 7.11 Limitation on Number of Shares Subject to Options. In no event may Options for more than 500,000 Shares be granted to any individual under the
Plan during any fiscal year period. 
  
 ARTICLE 8

 STOCK APPRECIATION RIGHTS 
  
 8.1 General. Stock Appreciation Rights will be subject to the terms and conditions set forth in Article 6 and this Article 8 and may contain such
additional terms and conditions, not inconsistent with the express terms of the Plan, as the Committee (or the Board with respect to Awards to Non-Employee Directors) deems desirable. 
  
 8.2 Nature of Stock Appreciation Right. A Stock Appreciation Right is an Award entitling a Participant to receive an
amount equal to the excess (or if the Committee determines at the time of grant, a portion of the excess) of the Fair Market Value of a Share of Common Stock on the date of exercise of the SAR over the base price, as described below, on the date of
grant of the SAR, multiplied by the number of Shares with respect to which the SAR has been exercised. The base price will be designated by the Committee in the Award Agreement for the SAR and may be the Fair Market Value of a Share on the grant
date of the SAR or such other higher or lower price as the Committee determines. 
  
 8.3 Exercise. A Stock Appreciation Right may be exercised by a Participant in accordance with procedures established by the Committee. The Committee may also provide that an SAR will be automatically exercised
on one or more specified dates or upon the satisfaction of one or more specified conditions. In the case of SARs granted to Reporting Persons, exercise of the SAR will be limited by the Committee to the extent required to comply with the applicable
requirements of Rule 16b-3 under the Exchange Act. 
  

 12 

 8.4 Form of Payment. Payment upon exercise of a Stock Appreciation Right may be made in cash, in
installments, in Shares, by issuance of a Deferred Compensation Option, or in any combination of the foregoing, or in any other form as the Committee determines. 
  
 8.5 Limitation on Number of Shares Subject to SARs. In no event may SARs for more than 500,000 Shares be granted to
any individual under the Plan during any fiscal year period. 
  
 ARTICLE 9 
 RESTRICTED AWARDS 
  

9.1 Types of Restricted Awards. Restricted Awards granted under the Plan may be in the form of either Restricted Shares or Restricted Units.

  
 (a) Restricted Shares. A Restricted
Share is an Award of Shares transferred to a Participant subject to such terms and conditions as the Committee deems appropriate, including, without limitation, restrictions on the sale, assignment, transfer, or other disposition of such Restricted
Shares and may include a requirement that the Participant forfeit such Restricted Shares back to Corporation upon termination of Participant’s employment (or service as an Advisor or Non-Employee Director) for specified reasons within a
specified period of time or upon other conditions, as set forth in the Award Agreement for such Restricted Shares. Each Participant receiving a Restricted Share will be issued a stock certificate in respect of such Shares, registered in the name of
such Participant, and will be required to execute a stock power in blank with respect to the Shares evidenced by such certificate. The certificate evidencing such Restricted Shares and the stock power will be held in custody by Corporation until the
Restrictions thereon will have lapsed. 
  
 (b)
Restricted Units. A Restricted Unit is an Award of units (with each unit having a value equivalent to one Share) granted to a Participant subject to such terms and conditions as the Committee deems appropriate, and may include a requirement
that the Participant forfeit such Restricted Units upon termination of Participant’s employment (or service as an Advisor or Non-Employee Director) for specified reasons within a specified period of time or upon other conditions, as set forth
in the Award Agreement for such Restricted Units. 
  
 9.2
General. Restricted Awards will be subject to the terms and conditions of Article 6 and this Article 9 and may contain such additional terms and conditions, not inconsistent with the express provisions of the Plan, as the Committee (or the
Board with respect to Awards to Non-Employee Directors) deems desirable. 
  

 13 

 9.3 Restriction Period. Restricted Awards will provide that such Awards, and the Shares subject to
such Awards, may not be transferred, and may provide that, in order for a Participant to Vest in such Awards, the Participant must remain in the employment (or remain as an Advisor or Non-Employee Director) of Corporation or its Subsidiaries,
subject to relief for reasons specified in the Award Agreement, for a period commencing on the date of the Award and ending on such later date or dates as the Committee designates at the time of the Award (the “Restriction Period”). During
the Restriction Period, a Participant may not sell, assign, transfer, pledge, encumber, or otherwise dispose of Shares received under or governed by a Restricted Award grant. The Committee, in its sole discretion, may provide for the lapse of
restrictions in installments during the Restriction Period. Upon expiration of the applicable Restriction Period (or lapse of Restrictions during the Restriction Period where the Restrictions lapse in installments) the Participant shall be entitled
to settlement of the Restricted Award or portion thereof, as the case may be. Although Restricted Awards will usually Vest based on continued employment (or service as an Advisor or Non-Employee Director) and Performance Awards under Article 10
shall usually Vest based on attainment of Performance Goals, the Committee, in its discretion, may condition Vesting of Restricted Awards on attainment of Performance Goals as well as continued employment (or service as an Advisor or Non-Employee
Director). In such case, the Restriction Period for such a Restricted Award will include the period prior to satisfaction of the Performance Goals. 
  
 9.4 Forfeiture. If a Participant ceases to be an employee, Advisor of Corporation or a Subsidiary or Non-Employee Director during the Restriction
Period for any reason other than reasons which may be specified in an Award Agreement (such as death, Disability, or Retirement), the Award Agreement may require that all non-Vested Restricted Awards previously granted to the Participant be
forfeited and returned to Corporation. 
  
 9.5 Settlement of
Restricted Awards. 
  
 (a) Restricted
Shares. Upon Vesting of a Restricted Share Award, the legend on such Shares will be removed and the Participant’s stock power will be returned and the Shares will no longer be Restricted Shares. The Committee may also, in its discretion,
permit a Participant to receive, in lieu of unrestricted Shares at the conclusion of the Restriction Period, payment in cash, installments, a Deferred Compensation Option equal to the Fair Market Value of the Restricted Shares as of the date the
Restrictions lapse, or in any other manner or combination of such methods as the Committee, in its sole discretion, determines. 
  
 (b) Restricted Units. Upon Vesting of a Restricted Unit Award, a Participant will be entitled to receive payment for Restricted
Units in an amount equal to the aggregate Fair Market Value of the Shares covered by such Restricted Units at the expiration of the Applicable Restriction Period. Payment in settlement of a Restricted Unit will be made as soon as practicable
following the conclusion of the applicable Restriction Period in cash, in installments, in Shares equal to the number of Restricted Units, by issuance of a Deferred Compensation Option, or in any other manner or combination of such methods as the
Committee, in its sole discretion, determines. 
  

 14 

 9.6 Rights as a Shareholder. A Participant will have, with respect to unforfeited Shares received
under a grant of Restricted Shares, all the rights of a shareholder of Corporation, including the right to vote the Shares, and the right to receive any cash dividends. Stock dividends issued with respect to Restricted Shares will be treated as
additional Shares covered by the grant of Restricted Shares and will be subject to the same Restrictions. 
  
 ARTICLE 10 
 PERFORMANCE AWARDS 
  
 10.1 General. Performance Awards will be subject to the terms and
conditions set forth in Article 6 and this Article 10 and may contain such other terms and conditions not inconsistent with the express provisions of the Plan, as the Committee (or the Board with respect to Awards to Non-Employee Directors) deems
desirable. 
  
 10.2 Nature of Performance Awards. A
Performance Award is an Award of units (with each unit having a value equivalent to one Share) granted to a Participant subject to such terms and conditions as the Committee deems appropriate, including, without limitation, the requirement that the
Participant forfeit such Performance Award or a portion thereof in the event specified performance criteria are not met within a designated period of time. 
  
 10.3 Performance Cycles. For each Performance Award, the Committee will designate a performance period (the “Performance Cycle”) with a
duration to be determined by the Committee in its discretion within which specified Performance Goals are to be attained. There may be several Performance Cycles in existence at any one time and the duration of Performance Cycles may differ from
each other. 
  
 10.4 Performance Goals. The Committee will
establish Performance Goals for each Performance Cycle on the basis of such criteria and to accomplish such objectives as the Committee may from time to time select. Performance Goals may be based on performance criteria for Corporation, a
Subsidiary, or an operating group, or based on a Participant’s individual performance. Performance Goals may include objective and subjective criteria. During any Performance Cycle, the Committee may adjust the Performance Goals for such
Performance Cycle as it deems equitable in recognition of unusual or nonrecurring events affecting Corporation, changes in applicable tax laws or accounting principles, or such other factors as the Committee may determine. 
  
 10.5 Determination of Awards. As soon as practicable after the end of
a Performance Cycle, the Committee will determine the extent to which Performance Awards have been earned on the basis of performance in relation to the established Performance Goals. 
  
 10.6 Timing and Form of Payment. Settlement of earned Performance Awards will be made to the Participant as soon as
practicable after the expiration of the Performance Cycle and the Committee’s determination under Section 10.5, in the form of cash, installments, Shares, Deferred Compensation Options, or any combination of the foregoing or in any other form
as the Committee determines. 
  

 15 

 10.7 Performance Goals for Executive Officers. The performance goals for Performance Awards
granted to executive officers of Corporation may relate to corporate performance, business unit performance, or a combination of both. 
  
 (a) Corporate performance goals will be based on financial performance goals related to the performance of Corporation as a whole and may
include one or more measures related to earnings, profitability, efficiency, or return to stockholders such as earnings per share, operating profit, stock price, costs of production, or other measures. 
  
 (b) Business unit performance goals will be based on a
combination of financial goals and strategic goals related to the performance of an identified business unit for which a Participant has responsibility. Strategic goals for a business unit may include one or a combination of objective factors
relating to success in implementing strategic plans or initiatives, introductory products, constructing facilities, or other identifiable objectives. Financial goals for a business unit may include the degree to which the business unit achieves one
or more objective measures related to its revenues, earnings, profitability, efficiency, operating profit, costs of production, or other measures. 
  
 (c) Any corporate or business unit goals may be expressed as absolute amounts or as ratios or percentages. Success may be measured against
various standards, including budget targets, improvement over prior periods, and performance relative to other companies, business units, or industry groups. 
  
 10.8 Award Limitations. The maximum number of Shares issuable with respect to Performance Awards granted to any individual executive officer may
not exceed 150,000 Shares for any calendar year. 
  
 ARTICLE 11

 OTHER STOCK-BASED AND COMBINATION AWARDS 
  

11.1 Other Stock-Based Awards. The Committee (or the Board with respect to Awards to Non-Employee Directors) may grant other Awards under the
Plan pursuant to which Shares are or may in the future be acquired, or Awards denominated in or measured by Share equivalent units, including Awards valued using measures other than the market value of Shares. Such Other Stock-Based Awards may be
granted either alone, in addition to, or in tandem with, any other type of Award granted under the Plan. 
  
 11.2 Combination Awards. The Committee may also grant Awards under the Plan in tandem or combination with other Awards or in exchange of Awards, or
in tandem or combination with, or as alternatives to, grants or rights under any other employee plan of Corporation, including the plan of any acquired entity. No action authorized by this section may reduce the amount of any existing benefits or
change the terms and conditions thereof without the Participant’s consent. 
  

 16 

 ARTICLE 12 
 DEFERRAL ELECTIONS 
  
 The
Committee may permit a Participant to elect to defer receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant by virtue of the exercise, earn-out, or Vesting of an Award made under the Plan. If any
such election is permitted, the Committee will establish rules and procedures for such payment deferrals, including, but not limited to: (a) payment or crediting of reasonable interest on such deferred amounts credited in cash, (b) the payment or
crediting of dividend equivalents in respect of deferrals credited in Share equivalent units, or (c) granting of Deferred Compensation Options. 
  
 ARTICLE 13 
 DIVIDEND EQUIVALENTS

  
 Any Awards may, at the discretion of the Committee, earn
dividend equivalents. In respect of any such Award that is outstanding on a dividend record date for Common Stock, the Participant may be credited with an amount equal to the amount of cash or stock dividends that would have been paid on the Shares
covered by such Award, had such covered Shares been issued and outstanding on such dividend record date. The Committee will establish such rules and procedures governing the crediting of dividend equivalents, including the timing, form of payment,
and payment contingencies of such dividend equivalents, as it deems appropriate or necessary. 
  
 ARTICLE 14 
 ADJUSTMENTS UPON CHANGES IN CAPITALIZATION, ETC. 
  
 14.1 Plan Does Not Restrict Corporation. The existence of the Plan and
the Awards granted hereunder will not affect or restrict in any way the right or power of the Board or the shareholders of Corporation to make or authorize any adjustment, recapitalization, reorganization, or other change in Corporation’s
capital structure or its business, any merger or consolidation of the Corporation, any issue of bonds, debentures, preferred or prior preference stocks ahead of or affecting Corporation’s capital stock or the rights thereof, the dissolution or
liquidation of Corporation or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding. 
  
 14.2 Adjustments by the Committee. In the event of any change in capitalization affecting the Common Stock of Corporation, such as a stock
dividend, stock split, recapitalization, merger, consolidation, split-up, combination or exchange of shares or other form of reorganization, or any other change affecting the Common Stock, such proportionate adjustments, if any, as the Committee, in
its sole discretion, may deem appropriate to reflect such change, will be made with respect to the aggregate number of Shares for which Awards in respect thereof may be granted under the Plan, the maximum number of Shares which may be sold or
awarded to any Participant, the number of Shares covered by each outstanding Award, 
  

 17 

 and the price per Share in respect of outstanding Awards. The Committee may also make such adjustments in the number of
Shares covered by, and price or other value of any outstanding Awards in the event of a spin-off or other distribution (other than normal cash dividends), of Corporation assets to shareholders. 
  
 ARTICLE 15 
 AMENDMENT AND TERMINATION 
  
 The Board may amend, suspend, or terminate the Plan or any portion of the Plan at any time, provided no amendment may be made without shareholder approval if such approval is required by applicable law or the applicable requirements of a
stock exchange or over-the-counter stock trading system. 
  
 ARTICLE 16 
 MISCELLANEOUS 
  
 16.1 Unfunded Plan. The Plan will be unfunded and Corporation will not be required to segregate any assets that may at any time be represented by
Awards under the Plan. Any liability of Corporation to any person with respect to any Award under the Plan will be based solely upon any contractual obligations that may be effected pursuant to the Plan. No such obligation of Corporation will be
deemed to be secured by any pledge of, or other encumbrance on, any property of Corporation. 
  
 16.2 Payments to Trust. The Committee is authorized (but has no obligation) to cause to be established a trust agreement or several trust agreements whereunder the Committee may make payments of amounts due or
to become due to Participants in the Plan. 
  
 16.3 Other
Corporation Benefit and Compensation Programs. Payments and other benefits received by a Participant under an Award made pursuant to the Plan will not be deemed a part of a Participant’s regular, recurring compensation for purposes of the
termination indemnity or severance pay law of any state or country and shall not be included in, or have any effect on, the determination of benefits under any other employee benefit plan or similar arrangement provided by Corporation or a
Subsidiary unless expressly so provided by such other plan or arrangements, or except where the Committee expressly determines that an Award or portion of an Award should be included to accurately reflect competitive compensation practices or to
recognize that an Award has been made in lieu of a portion of cash compensation. Awards under the Plan may be made in combination with or in tandem with, or as alternatives to, grants, awards, or payments under any other Corporation or Subsidiary
plans, arrangements, or programs. The Plan notwithstanding, Corporation or any Subsidiary may adopt such other compensation programs and additional compensation arrangements as it deems necessary to attract, retain, and reward employees and
directors for their service with Corporation and its Subsidiaries. 
  

 18 

 16.4 Securities Law Restrictions. No Shares may be issued under the Plan unless counsel for
Corporation is satisfied that such issuance will be in compliance with applicable federal and state securities laws. Certificates for Shares delivered under the Plan may be subject to such stop-transfer orders and other restrictions as the Committee
may deem advisable under the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Common Stock is then listed, and any applicable federal or state securities law. The Committee may
cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. 
  
 16.5 Governing Law. Except with respect to references to the Code or federal securities laws, the Plan and all actions taken thereunder shall be
governed by and construed in accordance with the laws of the state of Delaware. 
  
 ARTICLE 17 
 SHAREHOLDER APPROVAL 
  
 The Plan is expressly subject to the approval of the Plan by the shareholders at the 2000 annual meeting of Epitope Inc.’s
shareholders. 
  

 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]